Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Merck KGaA
  6. News
  7. Summary
    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : Raises Precigen Stake to 14.8% With Note Conversion

10/09/2020 | 08:06am EDT

By Colin Kellaher

Precigen Inc. on Friday said Germany's Merck KGaA elected to convert a $25 million note into common stock, raising its stake in the biopharmaceutical company to 14.8% from 11.6%.

The Germantown, Md., company issued the note to Merck in late 2018 as part of a deal in which Merck reassigned to Precigen its exclusive chimeric antigen receptor T-cell development rights.

Germany's Merck, which remains Precigen's second-largest shareholder, also received $150 million in stock as part of the transaction.

Precigen said the note would have otherwise converted in December.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-09-20 0805ET

Stocks mentioned in the article
ChangeLast1st jan.
MERCK KGAA -1.50% 151.45 Delayed Quote.7.91%
PRECIGEN, INC. -2.67% 6.56 Delayed Quote.-35.69%
All news about MERCK KGAA
06/15MERCK KGAA  : Berenberg gives a Neutral rating
MD
06/10Volkswagen, Nine Others Set Up Quantum Technology & Application Consortium
MT
06/10MERCK  : Obtains Halal Certifications For All Cosmetics Products
MT
06/10PRESS RELEASE : ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopip..
DJ
06/09MERCK KGAA  : UBS reaffirms its Neutral rating
MD
06/02Germany to build up reserve vaccine capacity to fight future pandemics
RE
06/02PRESS RELEASE : CureVac Appoints Klaus Edvardsen as Chief Development Officer
DJ
06/01Immutep, Merck KGaA Expand Collaboration in Solid Tumors
MT
06/01Merck KgaA Partners With Immutep For Trial In Solid Tumor Patients
MT
06/01Immutep in Collaboration, Supply Agreement With Merck KGaA
DJ
More news
Financials
Sales 2021 18 882 M 22 652 M 22 652 M
Net income 2021 2 551 M 3 061 M 3 061 M
Net Debt 2021 8 694 M 10 431 M 10 431 M
P/E ratio 2021 25,5x
Yield 2021 1,00%
Capitalization 65 847 M 79 795 M 78 995 M
EV / Sales 2021 3,95x
EV / Sales 2022 3,65x
Nbr of Employees 57 850
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 150,97 €
Last Close Price 151,45 €
Spread / Highest target 22,2%
Spread / Average Target -0,32%
Spread / Lowest Target -26,0%
EPS Revisions
Managers and Directors
NameTitle
Belén Garijo López Chairman-Executive Board & CEO
Marcus Kuhnert Chief Financial Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Nilesh Kumar Senior Investment Director
Christian Raabe Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA7.91%81 066
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD49.38%37 612
KYOWA KIRIN CO., LTD.36.11%18 418
SK BIOPHARMACEUTICALS CO., LTD.-26.92%8 333
BETTA PHARMACEUTICALS CO., LTD.-6.30%6 681
YUHAN CORPORATION-15.05%3 758